Patent intelligence · US
US 11364251
Pharmaceutical formulation
Pharmaceutical formulation
Patent details — US 11364251
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 21, 2022
- Expiration
- Jun 16, 2042
- Applicant
- Semnur Pharmaceuticals, Inc.
- Claims
- 20
- CPC classes
- A61K, A61K31/573, A61K31/58, A61K31/661
Quick answer
US 11364251 (Pharmaceutical formulation) is held by Semnur Pharmaceuticals, Inc.. Status: granted. Granted Jun 21, 2022. Expires Jun 16, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Semnur Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/573, A61K31/58, A61K31/661, A61K45/06, A61K47/36
More from Semnur Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12285485
Methods of treating pain
granted -
US 12016867
Methods of treating inflammation and/or pain
granted -
US 11020485
Pharmaceutical formulation
granted -
US 10744144
Pharmaceutical formulation
granted -
US 10500284
Pharmaceutical formulation
granted -
US 10117938
Pharmaceutical formulation
granted -
US 9833460
Pharmaceutical formulation
granted
Frequently asked questions
What is US patent 11364251?
US 11364251 (Pharmaceutical formulation) is held by Semnur Pharmaceuticals, Inc.. Status: granted. Granted Jun 21, 2022. Expires Jun 16, 2042 (16 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11364251?
Semnur Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8 pharmaceutical patents for this assignee.
When does US 11364251 expire?
Our index shows an expiration date of Jun 16, 2042 (16 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.